Equities

Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Ltd

Actions
  • Price (INR)2,295.00
  • Today's Change-44.95 / -1.92%
  • Shares traded1.20k
  • 1 Year change+68.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 05:55 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments2933011
Total Receivables, Net1,3758050
Total Inventory4292.8716
Prepaid expenses------
Other current assets, total------
Total current assets2,09711377
Property, plant & equipment, net23253.09
Goodwill, net93----
Intangibles, net0.280.500
Long term investments20520631
Note receivable - long term139047
Other long term assets6.260.120.05
Total assets2,573347159
LIABILITIES
Accounts payable9373547
Accrued expenses0.690.220.15
Notes payable/short-term debt8300
Current portion long-term debt/capital leases2.148.540.93
Other current liabilities, total4723844
Total current liabilities1,4958292
Total long term debt30710.99
Total debt115791.92
Deferred income tax00--
Minority interest175----
Other liabilities, total4.622.751.80
Total liabilities1,70415595
SHAREHOLDERS EQUITY
Common stock151110.00
Additional paid-in capital505420
Retained earnings (accumulated deficit)34813954
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.77----
Total equity86919164
Total liabilities & shareholders' equity2,573347159
Total common shares outstanding5.894.345.89
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.